The 2020 vancomycin guidelines recommend a Bayesian methodology for AUC-guided dosing.
- InsightRX Nova is designed to achieve target AUCs, which can help reduce the risk of adverse events.
- As almost ¼ of patients in the U.S. experience an adverse event*, choose the precision dosing platform used on a patient every second.
*https://www.nejm.org/doi/full/10.1056/NEJMsa2206117
InsightRX Nova is not considered to be a medical device in the U.S.
and has not been submitted to the FDA for review or clearance
Learn More: https://www.insight-rx.com
This post is related to:
Clinical Monitoring, Surveillance, Insights